|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
10/31/2012 9:08:45 AM
BOSTON, Oct. 30, 2012 /PRNewswire/ -- PAREXEL International Corporation (NASDAQ: PRXL) today reported financial results for the first quarter of Fiscal Year 2013, which ended on September 30, 2012.
For the three months ended September 30, 2012 service revenue increased by 25.4% to $394.8 million compared with $314.7 million in the prior year period. Excluding the negative impact from foreign exchange movements in the current quarter of $7.6 million, revenue increased 27.9%. Operating income as reported under Generally Accepted Accounting Principles (GAAP) totaled $29.8 million, or 7.5% of service revenue, in the first quarter of Fiscal Year 2013, as compared with $12.5 million, or 4.0% of service revenue, in the comparable quarter of the prior year. GAAP net income for the quarter totaled $15.1 million, or $0.25 per diluted share, compared with a GAAP net income of $9.6 million, or $0.16 per diluted share, for the quarter ended September 30, 2011.
|
|
|
|
|
|
|
|
|
|
|